Burris, Howard A.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 3,669

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 2,863

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 2,810

Ribociclib as first-line therapy for HR-positive, advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 2,039

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet

Inflammasome and immune disordersInflammatory Biomarkers in Disease Prognosis

Cited by 1,344

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Oh, D.-Y., Ruth He, A., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Ah Lee, M., Kitano, M., et al. (2022) · NEJM Evidence

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 1,217

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 1,125

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., et al. (2018) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 876

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., et al. (2022) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 791

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 574

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 573

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 552

Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from MyPathway, an open-label, phase IIa multiple basket study

Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 506

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 259

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

Petrylak, D. P., Gao, X., Vogelzang, N. J., Garfield, M. H., Taylor, I., Dougan Moore, M., Peck, R. A., & Burris, H. A. (2020) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 169

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology

Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and Treatment

Cited by 165

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Burris, H. A., Patel, M. R., Cho, D. C., Clarke, J. M., Gutierrez, M., Zaks, T. Z., Frederick, J., Hopson, K., Mody, K., Binanti-Berube, A., et al. (2019) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 144

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

Gainor, J. F., Patel, M. R., Weber, J. S., Gutierrez, M., Bauman, J. E., Clarke, J. M., Julian, R., Scott, A. J., Geiger, J. L., Kirtane, K., et al. (2024) · Cancer Discovery

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 124

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology

Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and Mutations

Cited by 115

Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer

Hecht, J. R., Mitchell, E., Neubauer, M. A., Burris, H. A., Swanson, P., Lopez, T., Buchanan, G., Reiner, M., Gansert, J., & Berlin, J. (2010) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 110

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

Grilley-Olson, J. E., Bedard, P. L., Fasolo, A., Cornfeld, M., Cartee, L., Razak, A. R. A., Stayner, L.-A., Wu, Y., Greenwood, R., Singh, R., et al. (2016) · Investigational New Drugs

PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK Pathways

Cited by 81

Treatment of Advanced Renal Cell Carcinoma with the Combination Bevacizumab/Erlotinib/Imatinib: A Phase I/II Trial

Hainsworth, J. D., Spigel, D. R., Sosman, J. A., Burris, H. A., Farley, C., Cucullu, H., Yost, K., Hart, L. L., Sylvester, L., Waterhouse, D. M., et al. (2007) · Clinical Genitourinary Cancer

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 80

A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer

Kindler, H. L., Burris, H. A., Sandler, A. B., & Oliff, I. A. (2009) · Investigational New Drugs

Biochemical and Molecular ResearchAdenosine and Purinergic Signaling

Cited by 79

A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial

Ou, S. I., Koczywas, M., Ulahannan, S., Janne, P., Pacheco, J., Burris, H., McCoach, C., Wang, J. S., Gordon, M., Haura, E., et al. (2020) · Journal of Thoracic Oncology

Protein Tyrosine PhosphatasesLung Cancer Treatments and Mutations

Cited by 73